Palo Alto Investors »

Sight Sciences shares owned by Palo Alto Investors

Quarter-by-quarter ownership of Sight Sciences (SGHT) shares owned by Palo Alto Investors from 13F filings

Historical chart of Palo Alto Investors investment in Sight Sciences

Tip: Access up to 7 years of quarterly data

All positions including Sight Sciences held by Palo Alto Investors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sight Sciences by Palo Alto Investors

Quarter filed Position value Share count Share price at filing
2023-12-31 $897k 174k 5.16

More positions owned by Palo Alto Investors

Insmed Com Par $.01 (INSM)
Amicus Therapeutics (FOLD)
BioMarin Pharmaceutical (BMRN)
Biogen Idec (BIIB)
United Therapeutics Corporation (UTHR)
ACADIA Pharmaceuticals (ACAD)
Prothena Corp SHS (PRTA)
Revance Therapeutics (RVNC)
Staar Surgical Com Par $0.01 (STAA)
Alnylam Pharmaceuticals (ALNY)
eHealth (EHTH)
Sage Therapeutics (SAGE)
Sarepta Therapeutics (SRPT)
Iovance Biotherapeutics (IOVA)
Alkermes SHS (ALKS)

View all positions for Palo Alto Investors

Top funds holding Sight Sciences

Bank of America Corporation
UBS Group
Jackson Square Partners
Vanguard Group
Jpmorgan Chase & Co
Apollo Management Holdings
D. E. Shaw & Co
Jacobs Levy Equity Management
Charles Schwab Investment Management
Point72 Asset Management
Palo Alto Investors
Squarepoint Ops
Bank Of Montreal
Dimensional Fund Advisors
Jane Street

View all funds holding Sight Sciences